 |
3 Products |  |
8 Diseases | | 3 Products |
|
1 Trial |  |
20 News |  |
- || KBA1412 / Kling Bio
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Monotherapy, Metastases: Study of KBA1412 in Participants With Advanced Solid Malignant Tumors (clinicaltrials.gov) - Aug 28, 2024
P1, N=16, Completed, Sponsor: Kling Biotherapeutics B.V.
Recruiting --> Completed | N=106 --> 16 | Trial completion date: Jan 2025 --> Jul 2024 | Trial primary completion date: Jan 2025 --> Jul 2024
- | KBA1412 / Kling Bio
New P1 trial, Monotherapy, Metastases: Study of KBA1412 in Participants With Advanced Solid Malignant Tumors (clinicaltrials.gov) - Aug 15, 2022
P1, N=106, Recruiting, Sponsor: Kling Biotherapeutics B.V.
- | AIM-102 / AIM Therap, NexImmune
Clinical, Journal: COMPLEX VISUAL ASSESSMENT OF STRUCTURAL CHANGES IN PANCREAS IN THE PATIENTS WITH CHRONIC PANCREATITIS. (Pubmed Central) - Nov 14, 2019
In the present study, in order to achieve our aim 102 patients with chronic pancreatitis underwent general physical and laboratory examination...The imaging of structural changes in the pancreas requires the combination of instrumental and diagnostic methods, in particular EGD and ultrasound examination, as well as ERCP in order to make accurate assessment of the pancreatic ducts and parenchymatous parameters of the pancreas in case of a relapsing course of disease. The analysis of the identified disorders of the pancreatic ducts and parenchyma makes it possible to adjust treatment protocols to provide proper clinical care to patients with chronic pancreatitis.
- | CR-8020 / AIM Therap
Enrollment change, Trial withdrawal: A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR8020 in Japanese Healthy Participants (clinicaltrials.gov) - Apr 20, 2019
P1, N=0, Withdrawn, Sponsor: Janssen Pharmaceutical K.K.
The analysis of the identified disorders of the pancreatic ducts and parenchyma makes it possible to adjust treatment protocols to provide proper clinical care to patients with chronic pancreatitis. N=12 --> 0 | Not yet recruiting --> Withdrawn
- CR-8020 / AIM Therap
Trial withdrawal: Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection (clinicaltrials.gov) - Mar 2, 2014
P2, N=0, Withdrawn, Sponsor: Crucell Holland BV
N=12 --> 0 | Not yet recruiting --> Withdrawn Suspended --> Withdrawn
- CR-8020 / AIM Therap
Enrollment change: Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection (clinicaltrials.gov) - Mar 2, 2014
P2, N=0, Withdrawn, Sponsor: Crucell Holland BV
Suspended --> Withdrawn N=262 --> 0
- | CR-8020 / AIM Therap
Trial completion: Evaluation of the Protective Efficacy and Safety of CR8020 in an Influenza Challenge (clinicaltrials.gov) - Mar 2, 2014
P2a, N=22, Completed, Sponsor: Crucell Holland BV
N=262 --> 0 Recruiting --> Completed
- | AIM-102 / AIM Therap
Trial completion: Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic Asthma (clinicaltrials.gov) - Feb 11, 2014
P2, N=11, Completed, Sponsor: AIM Therapeutics Inc.
Recruiting --> Completed Not yet recruiting --> Completed
- | CR-8020 / AIM Therap
New P1 trial: A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR8020 in Japanese Healthy Participants (clinicaltrials.gov) - Dec 17, 2013
P1, N=12, Not yet recruiting, Sponsor: Janssen Pharmaceutical K.K.
- ||| CR-8020 / AIM Therap
Trial completion: Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses (clinicaltrials.gov) - Dec 17, 2013
P1, N=64, Completed, Sponsor: Crucell Holland BV
Not yet recruiting --> Completed Active, not recruiting --> Completed
- CR-8020 / AIM Therap
New P2 trial: Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection (clinicaltrials.gov) - Nov 21, 2013
P2, N=0, Withdrawn, Sponsor: Crucell Holland BV
- | CR-8020 / AIM Therap
New P2a trial: Evaluation of the Protective Efficacy and Safety of CR8020 in an Influenza Challenge (clinicaltrials.gov) - Sep 8, 2013
P2a, N=22, Completed, Sponsor: Crucell Holland BV
- || CR-8020 / AIM Therap
Enrollment change: Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses (clinicaltrials.gov) - Jul 9, 2013
P1, N=64, Completed, Sponsor: Crucell Holland BV
Active, not recruiting --> Completed N=40 --> 64
- ||| CR-8020 / AIM Therap
New P1 trial: Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses (clinicaltrials.gov) - Dec 26, 2012
P1, N=64, Completed, Sponsor: Crucell Holland BV
- | AIM-102 / AIM Therap
New P2 trial: Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic Asthma (clinicaltrials.gov) - Dec 28, 2011
P2, N=11, Completed, Sponsor: AIM Therapeutics Inc.